4568.T

$2977.00

Market ClosedAs of Mar 18, 6:30 AM UTC

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Insider Monkey
Mar 16, 2026

Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp

AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now. Guggenheim lifted the price target on AstraZeneca PLC (NASDAQ:AZN) to 16,000 GBp from 15,500 GBp on March 10, reiterating a Buy rating on the shares and telling investors that it is updating its model after the company’s fiscal 2025 […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 15, 2026

AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment

AstraZeneca PLC (NYSE:AZN) is one of Goldman Sachs top healthcare stocks. On March 9, AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo secured Priority Review in the US for Enhertu, their candidate drug for patients with HER2-positive breast cancer. The priority review comes on the heels of the Food and Drug Administration granting Enhertu Breakthrough Therapy Designation, […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 10, 2026

AstraZeneca Oncology Updates Prompt Fresh Look At Valuation And Growth Potential

Health Canada has approved AstraZeneca's Koselugo for adults with neurofibromatosis type 1 and inoperable plexiform neurofibromas. The US FDA has granted Priority Review to the supplemental application for ENHERTU in early stage HER2 positive breast cancer, filed by AstraZeneca and Daiichi Sankyo. For investors watching AstraZeneca (LSE:AZN), these updates are closely aligned with its rare disease and oncology focus. Koselugo’s approval in Canada adds an option where treatment choices for...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
BioPharma Dive
Mar 6, 2026

Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Medical Device Network
Mar 5, 2026

Daiichi and GAIA join forces to commercialise digital cardiovascular therapy

Pharma companies are increasingly combining the strengths of pharmaceutical and digital health interventions to improve outcomes.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.